Uveitis clinical trials at University of California Health

5 in progress, 4 open to eligible people

Showing trials for

  • Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

    open to eligible people ages 18-75

    The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).

    at UCLA

  • Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

    open to eligible people ages 18 years and up

    The proposed study is a block-randomized, controlled trial to evaluate the effects of a digital meditation and mindfulness practice on mental health in patients with non-infectious uveitis.

    at UCSF

  • OCS-01 in Subjects with Uveitis Related and Post Surgical Macular Edema

    open to eligible people ages 18 years and up

    The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01. Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision. In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery. Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

    at UCLA

  • Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

    open to eligible people ages 18 years and up

    This is a multi-center randomized controlled evaluator-masked trial designed to compare metagenomic deep sequencing (MDS) versus standard of care testing for improvement of outcomes for intraocular infections. Patients with presumed intraocular infections who meet the eligibility criteria will be randomized to receive MDS testing results or not to receive MDS testing results. All patients will receive standard-of-care testing to guide management. Enrolled patients will be followed at week 2, week 3-6 (randomization visit), and at 4 weeks after the randomization visit. The proportions of patients who received the appropriate therapy and the proportions of patients with improved outcome will be compared between arms. Patient quality of life, MDS performance, and the provider certainly of belief will be collected.

    at UC Davis UCLA UCSF

  • Adalimumab in JIA-associated Uveitis Stopping Trial

    Sorry, in progress, not accepting new patients

    The proposed study is a stratified, block-randomized, double-masked, controlled trial to determine the feasibility of discontinuing adalimumab treatment in patients with quiescent uveitis associated with juvenile idiopathic arthritis (JIA) or chronic anterior uveitis (CAU).

    at UC Davis UCSF

Our lead scientists for Uveitis research studies include .

Last updated: